ARLINGTON, Mass. — August 8, 2025 — Leads & Copy — KALA BIO, Inc. (NASDAQ:KALA) has completed patient enrollment in its Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED). The company anticipates topline data by the end of September 2025. As of June 30, 2025, KALA BIO’s cash resources were $31.9 million, which are expected to fund operations into 1Q 2026.
According to Todd Bazemore, interim Chief Executive Officer of KALA BIO, the second quarter of 2025 was a pivotal period for KALA, marked by the completion of patient enrollment in the CHASE trial and the continued execution of its clinical and corporate strategy. The company believes the CHASE trial has the potential to serve as a pivotal trial required to support a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), contingent on positive results and subject to discussions with regulatory authorities.
KALA BIO’s innovative pipeline is based on its proprietary mesenchymal stem cell secretome (MSC-S) platform, which the company believes may enable it to generate product candidates for a range of rare, ocular diseases. KALA is also exploring the potential of KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD), and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases.
KALA BIO reported financial results for the second quarter ended June 30, 2025. General and administrative (G&A) expenses were $4.6 million, compared to $4.3 million for the same period in 2024. Research and development (R&D) expenses were $6.2 million, compared to $5.3 million for the same period in 2024. Net loss was $11.2 million, or $1.71 per share, compared to a net loss of $9.6 million, or $3.16 per share, for the same period in 2024.
Investor Contact: Taylor Steiner, taylor.steiner@precisionaq.com, 212-362-1200
Source: KALA BIO
